Bo Pang, DO
Facial Plastic Surgery · Brunswick, MENPI 1134579519
Payments from drug & device makers
Across 86 payments — averaging $76.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerin Medical Inc.$2K
- Intersect ENT, Inc.$2K
- Acclarent, Inc$1K
- Regeneron Healthcare Solutions, Inc.$482
- Stryker$445
- Integra Lifesciences Corporation$272
- plus $433 from 6 others
What the payments were for
- Consulting fees$1,50023%
- Food & beverage$4,87874%
- Education$1723%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerin Medical Inc. | 9 | $2,276 |
| Intersect ENT, Inc. | 13 | $1,570 |
| Acclarent, Inc | 23 | $1,071 |
| Regeneron Healthcare Solutions, Inc. | 20 | $482 |
| Stryker | 5 | $445 |
| Integra Lifesciences Corporation | 5 | $272 |
| Checkpoint Surgical, Inc | 2 | $157 |
| Smith+Nephew | 1 | $74 |
| Zimmer Biomet | 2 | $63 |
| GSK | 3 | $54 |
| Medtronic | 1 | $50 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVAER STYLUS$1,631
- SINUVA$761
- PROPEL$708
- Relieva Spinplus$341
- Vivaer RF Stylus$265
- TruDi Nav Cable$233
- Acclarent Aera$230
- SCOPIS ENT$170
- XPRESS ENT DILATION SYSTEM$167
- RHINAER STYLUS$131
- DUPIXENT$125
- Acclarent Navwire$122
- Relieva Tract$108
- Checkpoint Stimulators$107
How this compares
Too few facial plastic surgery providers in Maineto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 29 | $4,020 |
| Azelastine Hcl | 42 | $1,992 |
| Fluticasone Propionate | 86 | $1,549 |
| Ipratropium Bromide | 47 | $1,544 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 30 | $424 |
| Mupirocin | 17 | $114 |
| Prednisone | 17 | $28 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.